Immunic to Participate in Investor and Scientific Conferences in February
Provided By PR Newswire
Last update: Feb 4, 2025
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:
Read more at prnewswire.com
